Actively Recruiting
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Led by Thomas Jefferson University · Updated on 2025-11-28
100
Participants Needed
1
Research Sites
137 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective trial investigates the approach of G-CSF with risk-adapted Plerixafor use for stem cell mobilization in patients undergoing autologous stem cell transplantation. Since FDA approval in 2008, Plerixafor has been combined with G-CSF to mobilize stem cells, though this regimen has been associated with a potentially higher incidence of engraftment syndrome. The trial aims to evaluate whether using G-CSF alone, with selective use of Plerixafor, can achieve adequate stem cell collection while possibly reducing the incidence of engraftment syndrome.
CONDITIONS
Official Title
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Undergoing autologous stem cell transplant for multiple myeloma, Hodgkin lymphoma, or non-Hodgkin lymphoma
- Karnofsky performance status of 60% or higher
- Meets the TJUH BMT SOP guidelines for Patient Criteria for Autologous HSCT
- Adequate organ function with left ventricular ejection fraction of 40% or higher
- Adjusted diffusing capacity for carbon monoxide (DLCO) 45% or higher of predicted corrected for hemoglobin
- Adequate liver function: serum bilirubin less than 1.8, AST or ALT less than 2.5 times upper limit of normal
- Serum creatinine 2.0 mg/dl or less and/or creatinine clearance greater than 40 ml/min (except multiple myeloma patients receiving high dose Melphalan conditioning)
- Willingness to use contraception if of childbearing potential
- Ability to give informed consent or availability of guardian for consent and assistance
- Life expectancy greater than 12 months, excluding the disease being treated by autologous HSCT
- Prior stem cell mobilization with G-CSF or biosimilars with or without plerixafor
You will not qualify if you...
- Uncontrolled HIV infection
- Uncontrolled bacterial infection
- Active central nervous system disease
- Pregnancy or lactation
- Presence of another malignancy except skin cancer requiring only local treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States, 19107
Actively Recruiting
Research Team
X
Xia Bi, MD, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here